Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer

被引:32
|
作者
Takamori, Shinkichi [1 ]
Toyokawa, Gouji [1 ]
Okamoto, Isamu [2 ]
Takada, Kazuki [1 ,3 ]
Kozuma, Yuka [1 ]
Matsubara, Taichi [1 ]
Haratake, Naoki [1 ]
Akamine, Takaki [1 ]
Katsura, Masakazu [1 ]
Mukae, Nobutaka [4 ]
Shoji, Fumihiro [1 ]
Okamoto, Tatsuro [1 ]
Oda, Yoshinao [3 ]
Iwaki, Toru [5 ]
Iihara, Koji [4 ]
Nakanishi, Yoichi [2 ]
Maehara, Yoshihiko [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan
[2] Kyushu Univ, Chest Grad Sch Med Sci, Res Inst Dis, Fukuoka, Japan
[3] Kyushu Univ, Dept Anat Pathol, Grad Sch Med Sci, Fukuoka, Japan
[4] Kyushu Univ, Dept Neurosurg, Grad Sch Med Sci, Fukuoka, Japan
[5] Kyushu Univ, Dept Neuropathol, Neurol Inst, Grad Sch Med Sci, Fukuoka, Japan
关键词
Programmed cell death-ligand 1; immunotherapy; non-small cell lung cancer; BRAIN METASTASES; PREDICTIVE BIOMARKERS; EXPRESSION; PD-L1; PEMBROLIZUMAB; ALECTINIB; NIVOLUMAB; ERLOTINIB; CHEMOTHERAPY; CRIZOTINIB;
D O I
10.21873/anticanres.11813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being >= 5% were considered PD-L1-positive. Results: The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14%) and 2 (10%) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048). Conclusion: Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC.
引用
收藏
页码:4223 / 4228
页数:6
相关论文
共 50 条
  • [41] Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer
    Nagasaki, Yusuke
    Taki, Tetsuro
    Nomura, Kotaro
    Tane, Kenta
    Miyoshi, Tomohiro
    Samejima, Joji
    Aokage, Keiju
    Ohtani-Kim, Seiyu Jeong-Yoo
    Kojima, Motohiro
    Sakashita, Shingo
    Sakamoto, Naoya
    Ishikawa, Shumpei
    Suzuki, Kenji
    Tsuboi, Masahiro
    Ishii, Genichiro
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (07): : 1158 - 1168
  • [42] PROGRAMMED CELL DEATH-LIGAND 1 EXPRESSION AND IMMUNOSCORE IN STAGE II AND III NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY
    Ishii, Hidenobu
    Azuma, Koichi
    Naito, Yoshiko
    Matsuo, Norikazu
    Tokito, Takaaki
    Kinoshita, Takashi
    Yamada, Kazuhiko
    Hoshino, Tomoaki
    RESPIROLOGY, 2017, 22 : 113 - 113
  • [43] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
    Arbour, Kathryn C.
    Mezquita, Laura
    Long, Niamh
    Rizvi, Hira
    Auclin, Edouard
    Ni, Andy
    Martinez-Bernal, Gala
    Ferrara, Roberto
    Lai, W. Victoria
    Hendriks, Lizza E. L.
    Sabari, Joshua K.
    Caramella, Caroline
    Plodkowski, Andrew J.
    Halpenny, Darragh
    Chaft, Jamie E.
    Planchard, David
    Riely, Gregory J.
    Besse, Benjamin
    Hellmann, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2872 - +
  • [44] Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
    Garg, Gaurav
    Prasad, Kuruswamy Thurai
    Singh, Navneet
    Gupta, Parul
    Muthu, Valliappan
    Das, Ashim
    Bal, Amanjit
    JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2021, 55 (06) : 398 - 405
  • [45] Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers
    Liam, Chong Kin
    Yew, Chian Yih
    Pang, Yong Kek
    Wong, Chee Kuan
    Poh, Mau Ern
    Tan, Jiunn Liang
    Soo, Chun Ian
    Loh, Thian Chee
    Chin, Ka Kiat
    Munusamy, Vijayan
    Liam, Yong Sheng
    Ibrahim, Nur Husna
    BMC CANCER, 2023, 23 (01)
  • [46] Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer
    Kumar, Manish
    Guleria, Bhupesh
    Swamy, Shivashankar
    Soni, Sneha
    LUNG INDIA, 2020, 37 (02) : 145 - 150
  • [47] A Review of Artificial Intelligence in Precise Assessment of Programmed Cell Death-ligand 1 and Tumor-infiltrating Lymphocytes in Non-Small Cell Lung Cancer
    Wu, Jianghua
    Lin, Dongmei
    ADVANCES IN ANATOMIC PATHOLOGY, 2021, 28 (06) : 439 - 445
  • [48] Radiation therapy induces an abscopal effect and upregulates programmed death-ligand 1 expression in a patient with non-small cell lung cancer
    Morita, Yutaka
    Saijo, Atsuro
    Nokihara, Hiroshi
    Mitsuhashi, Atsushi
    Yoneda, Hiroto
    Otsuka, Kenji
    Ogino, Hirokazu
    Bando, Yoshimi
    Nishioka, Yasuhiko
    THORACIC CANCER, 2022, 13 (07) : 1079 - 1082
  • [49] Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers
    Chong Kin LIAM
    Chian Yih YEW
    Yong Kek PANG
    Chee Kuan WONG
    Mau Ern POH
    Jiunn Liang TAN
    Chun Ian SOO
    Thian Chee LOH
    Ka Kiat CHIN
    Vijayan MUNUSAMY
    Yong Sheng LIAM
    Nur Husna IBRAHIM
    BMC Cancer, 23
  • [50] Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer
    Seok-Hyun Kim
    Se-Il Go
    Dae Hyun Song
    Sung Woo Park
    Hye Ree Kim
    Inseok Jang
    Jong Duk Kim
    Jong Sil Lee
    Gyeong-Won Lee
    British Journal of Cancer, 2019, 120 : 547 - 554